Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- Most Pharmacists to Use Norvasc Despite Availability of Generics
June 30, 2008
- 23 Reported/New Kit Products Listed
June 30, 2008
- IHEP Presents Report on Use of Generics in the West
June 30, 2008
- 16 APIs, Including Adapalene, to Be Approved
June 30, 2008
- Draft Basic Policies 2008 Approved Calling For Maintenance of \1.1 Tril. Cutting Plan
June 30, 2008
- Distribution Practices Must Be Improved to Review FPMAJ's Pricing Reform Proposal: Mr Tsushima
June 30, 2008
- TOPICS／Japanese Society for Treatment of Obesity Inaugurated
June 30, 2008
- Improvements of Distribution Practices Essential for Pricing System Reform: Mr Nagano
June 30, 2008
- Multiparty Group of Diet Members to Discuss Increases in Tobacco Tax
June 30, 2008
- REGULATORY NEWS IN BRIEF
June 30, 2008
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
June 30, 2008
- RNAi Drugs Development Race Heats Up with Entry of Kyowa Hakko
June 30, 2008
- Kyowa Hakko Licenses RNAi Drug for RSV Infection from Alnylam
June 30, 2008
- Annual Meeting of Japanese Society of Chemotherapy
June 30, 2008
- Okayama Univ. to Lead Gene Therapy Research for Prostate Cancer in Asians
June 30, 2008
- R&D NEWS IN BRIEF
June 30, 2008
- Yamato HD Proposes Direct Deal between Makers and Med. Institutions
June 23, 2008
- Daiichi Sankyo to Acquire Majority of Ranbaxy Shares
June 23, 2008
- Increase Share of Generics to 40%: Council
June 23, 2008
- GENERICS NEWS IN BRIEF
June 23, 2008
ページ
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Adeno-associated virus (AAV) gene therapies have long been viewed as carrying only a minimal risk of insertional mutagenesis — a…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…